Promising Liver Cure Turns Cancer Threat

Scientists working in a laboratory with microscopes and test tubes

Blocking a promising enzyme to treat fatty liver disease could quadruple cancer risk in aging livers, turning a hoped-for cure into a hidden threat.

Story Snapshot

University of Adelaide study in Science Advances shows Caspase-2 inhibition boosts liver tumors up to four times in mice.
Short-term benefits mask long-term dangers like chronic inflammation, fibrosis, and hepatocellular carcinoma.
Impacts 1 in 4 U.S. adults with fatty liver, plus global liver cancer toll of 760,000 deaths yearly.
Challenges pharma pipelines, demands longer safety studies before human trials.
Reinforces lifestyle changes over rushed drugs for metabolic liver diseases.

University of Adelaide Researchers Uncover Caspase-2 Paradox

Dr. Loretta Dorstyn and Professor Sharad Kumar at the University of Adelaide led the study published January 13, 2026, in Science Advances. They tested mice lacking functional Caspase-2, an enzyme targeted for fatty liver treatment. Young mice showed reduced fat buildup initially. Older mice developed severe issues. Tumors appeared at rates four times higher than controls, mimicking human liver cancer. This flips assumptions that Caspase-2 inhibition universally protects the liver.

Caspase-2 clears damaged liver cells, preventing polyploidy issues where cells gain extra DNA copies under stress. Without it, stressed hepatocytes survive but accumulate mutations. The liver processes fats, detoxifies blood, and regulates metabolism, making it prone to high-fat diet damage. Fatty liver progresses from simple fat (MASLD) to inflamed scarring (MASH), then cancer. This enzyme’s role grows critical with age.

Fatty Liver Epidemic Sets Global Crisis Stage

One in four U.S. adults battles fatty liver disease, driven by obesity and poor diets. Worldwide, liver cancer killed 760,000 in 2022 alone, ranking sixth in commonality. High-fat diets revert mature liver cells to stem-like states, per 2025 MIT research, aiding short-term survival but priming cancer. MASLD and MASH create inflammation and scars fostering mutations. Patients and doctors sought Caspase-2 blockers as a fix; now risks loom larger.

Pharma Pipelines Face Immediate Reckoning

Companies developing Caspase-2 inhibitors confront delays or cancellations. Physicians pause endorsements for unproven drugs. Patients adjust hopes, eyeing lifestyle shifts. Funding pivots to safer paths, like MIT-identified transcription factors. Regulatory bodies scrutinize trials, prioritizing lifespan studies. Short-term gains in young models deceived; elderly mice suffered most, mirroring human aging risks.

A promising fatty liver treatment may raise cancer risk: https://t.co/CvWjzMZT9R

— Ken Gusler (@kgusler) March 23, 2026

Dr. Dorstyn stated inhibiting Caspase-2 protects young animals short-term but proves detrimental long-term. Professor Kumar highlighted risks of chronic inflammation, fibrosis, and cancer later in life. These facts demand caution. Industry motives for profit clash with patient safety; evidence sides with researchers, upholding prudence over haste in American tradition.